Drugs / Danagalex
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07530796 | May 2026 → May 2029 expected | aspartylglucosaminuria | Rare Trait Hope | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Danagalex | “Danagalex, a self-complementary adeno-associated Virus Serotype 9 (AAV9) vector-mediated gene transfer of codon optimized human AGA gene, administered via intrathecal injection” NCT07530796 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “self-complementary adeno-associated Virus Serotype 9 (AAV9) vector-mediated gene transfer” NCT07530796 ↗ |
| Route | Intrathecal | “administered via intrathecal injection” NCT07530796 ↗ |
| Target | AGA | “codon optimized human AGA gene” NCT07530796 ↗ |